Winrevair is used for the treatment of adults with pulmonary arterial hypertension to increase exercise capacity, improve WHO functional class and reduce the risk of clinical worsening events.
The updated label with additional data reinforces the safety and efficacy profile of Biktarvy to treat pregnant people with HIV-1 with suppressed viral loads, the company said.
Biktarvy is the first and only INSTI-Based Single-Tablet regimen that is FDA approved and DHHS Guideline Recommended for people who are virologically suppressed with M184V/I resistance.
Balfaxar is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients.